Soraya is a board-certified MD graduated from Paris University specialized in Clinical Pharmacology and Biostatistics with 20 years of experience in Drug Development. She started her career in the academia before joining the industry with Orphan Europe, in the rare disease space. She then joined Sanofi for 9 years where she held increasing leadership positions within global R&D, leading gene therapy programs in cardiovascular and Ophthalmology. She took over the leadership of the Ophthalmology Division in 2012 and in this capacity, drove Sanofi strategy towards ocular gene therapy efforts while setting up a multidisciplinary R&D and business organization. Before joining Gyroscope mid-2017, Soraya served as SVP CMO at Lysogene, a biotech developing gene therapy treatment for rare CNS disorders. As a member of the executive team, she contributed to the successful listing of Lysogene on the European Stock Exchange Euronext.
At Gyroscope, Soraya serves as CEO and CMO driving the company s strategy and operations in developing gene therapies for the treatment of eye diseases linked to an unbalanced Complement System.
Simon graduated with a degree in Pharmacy from the University of Portsmouth. He started his pharmaceutical industry career in SmithKline Beecham with several commercial roles across Europe, Middle East and Asia. He has a broad therapeutic experience spanning more than 20 years in pharmaceuticals including biotechnology and CRO’s and most recently as SVP Corporate Strategy and Communication at Astellas Pharma Europe, and as a member of the Business Development Advisory Board for Sunstone Capital.
In senior positions across the Industry, he has been responsible for leading multi-disciplinary teams in developing Corporate and Business Development strategies. His focus has been on developing new business operating models, building a portfolio of new products and successfully bridging the development and commercial organisations to enhance the enterprise value.
At Gyroscope Simon serves as Vice President of Corporate Strategy, working closely with the rest of the Management team in bringing new complement-based gene therapies to patients.
Ian graduated from the University of Cambridge in 1992 with a PhD in Biotechnology. After a short period working for SAF developing downstream processes for high value, low volume products, Ian moved to SmithKline Beecham/GlaxoSmithKline to start a 17-year Analytical Scientist/Management career in Pharmaceutical Drug development. From June 2012, Ian transitioned to CMC Project Leadership in GSK’s Cell and Gene Therapy CMC platform leading development, validation and regulatory submission of Strimvelis, the world’s first approved ex-vivo autologous gene therapy. Ian has been VP of CMC at Gyroscope Therapeutics since January 2017.
Alex is an experienced regulatory affairs professional with more than 15 years of industry and academic experience. Alex holds a PhD from the University of Sheffield.
Prior to joining Gyroscope, Alex was VP Regulatory Affairs at Cell Medica, where he led EU regulatory activities for a portfolio of cell and gene therapies for the treatment of cancer. Alex also worked at Chiesi Farmaceutici, where he played an integral role in the development and approval of Holoclar, the first ophthalmic ATMP to receive marketing authorisation in Europe. As a consultant to the biopharm industry, Alex has been involved in leading the development, preparation and management of multiple regulatory submissions and has contributed to more than 25 cell and gene therapy programmes, as well as establishing a strong working relationship with regulators, both in Europe and the US.
Alex is the VP Regulatory Affairs at Gyroscope and leads all regulatory affairs activities on a strategic and operational level as well as serving on the management team.
Scott graduated from University College London in 1999 with a PhD in Genetics and moved to the Brunel Institute for Cancer Genetics and Pharmacogenomics at Brunel University (London) where he conducted postdoctoral research in the identification of tumour suppressor genes. In 2002 he moved to the Wellcome Trust Centre for Human Genetics in Oxford to work on the genetics of heart disease. He joined Oxford BioMedica in 2006 to start an 11 year career in gene and cell therapy Product Development and was ultimately responsible for R&D of the Company’s product pipeline as Head of Early Development. During this time he saw preclinical programmes progress into the clinic for chronic ocular conditions such as wet age-related macular degeneration, Stargardt disease and Usher syndrome.
Scott started as VP Research at Gyroscope Therapeutics in November 2017.
AMD is the leading cause of irreversible blindness in the elderly and today there is no effective treatment for the atrophic form of the diseaseView More +
Gyroscope Therapeutics Ltd is developing cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement systemView More +
Gyroscope was founded to explore the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD) and gene therapy as a mode of treatment delivery.View More +